



Test Report/ Certificate of Analysis

Date of Report July 10, 2026
To: USA Made Peptides
From: AxisPharm, LLC
Certificate ID Number: 10Jul2026-07

Results reported by: Lab Technician
Ning Yang


Review/Approved by: 
QA Director
Dawei Yue

Sample Received: Date: 06/29/2026
Receiving Condition: ☒ Acceptable ☐ Other: _____
Storage Condition: ☐ Room temperature ☐ -20°C ☒ -80°C
☐ Other: _____

Sample Name: TIRZEPATIDE, 30MG; Batch: TIRZ-30-161-26, BBD: 06/2028

Method(s): LCMS

Procedure(s): Results:



AxisPharm, LLC

Results only apply to tested Research Use Only samples within Test Report as received. Not for use in humans or animals. Analytical data apply only to the batch tested and do not indicate suitability for diagnostic or therapeutic use. Any unauthorized alteration, reproduction, or relabeling of this COA renders it invalid.



Test Report/ Certificate of Analysis

Sample Name	Amount Measured (mg)	MW (g/mol)	Detected	UV Purity (%)
TIRZEPATIDE, 30MG	28.7	4813.5	2408.1[M+2H], 1605.9[M+3H]	99.5%

Salts and sugars that serves as fillers in injectables/nasal sprays/oral stripes are not considered as impurities. Conclusion: The product comes with TIRZEPATIDE, 28.7MG with purity 99.5%.